However, the GLP-1 receptor/GIP receptor/GCGR triple agonist retatrutide showed strong glucose-lowering and weight-lowering efficacy (HbA1c reduction of 22.4 mmol/mol [2.01%] at 24 weeks and body weight reduction of 13.9% at 36 weeks, placebo subtracted) during a Phase 2 trial in overweight/obese individuals with type 2 diabetes [61]. The gene discussed is GCGR; the disease is type 2 diabetes mellitus.